From Oct 2013 ::: The innovation award we won from OTC Bulletin in March has yielded more than a good-looking plaque. Our products caught the attention of several interested parties including three of Europe’s largest pharmaceutical companies. We are actively exploring distribution and co-branding licensing proposals with all three. In each case these proposals offer significant potential advantages to the company. The most immediate would be product sales to companies with well-established, funded marketing and sales channels, and licensing agreements with royalty income. This strategy maintains our first-to-market advantage while giving us access to a good income stream and marketing power and access to capital (without further dilution). Another advantage would be the spill-over affect associated with this co-branding alliance on our other brands and obtaining additional distribution in other regions. http://www.bielcorp.com/investors/letter-from-the-president/
2014 Oxford Pharmascience Group (OXP) is sponsoring BIELhttp://www.oxfordpharmascience.com/content/investors/share_price.asp
News 
Market Data 
Discover 
AI
